Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Net Income (2019 - 2025)

BridgeBio Pharma's Net Income history spans 7 years, with the latest figure at -$194.6 million for Q4 2025.

  • For Q4 2025, Net Income rose 20.24% year-over-year to -$194.6 million; the TTM value through Dec 2025 reached -$666.6 million, down 32.55%, while the annual FY2025 figure was -$732.9 million, 34.89% down from the prior year.
  • Net Income for Q4 2025 was -$194.6 million at BridgeBio Pharma, down from -$149.2 million in the prior quarter.
  • Across five years, Net Income topped out at -$19.1 million in Q1 2024 and bottomed at -$244.0 million in Q4 2024.
  • The 5-year median for Net Income is -$161.3 million (2021), against an average of -$152.4 million.
  • The largest annual shift saw Net Income skyrocketed 86.59% in 2024 before it plummeted 640.71% in 2025.
  • A 5-year view of Net Income shows it stood at -$180.6 million in 2021, then rose by 19.62% to -$145.1 million in 2022, then plummeted by 32.37% to -$192.1 million in 2023, then dropped by 27.02% to -$244.0 million in 2024, then rose by 20.24% to -$194.6 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Net Income are -$194.6 million (Q4 2025), -$149.2 million (Q3 2025), and -$181.7 million (Q2 2025).